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General discussion and perspectives
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Inflammation is a naturally occurring process that exists as a first response of 
the immune system to infection, and as such it is considered a “good” process necessary 
for maintenance of body homeostasis. However, in the case of chronic inflammatory 
diseases like rheumatoid arthritis and glomerulonephritis, ongoing leukocyte activation 
and recruitment often leads to severe tissue disruption and loss of organ function. Many 
studies hypothesized, and demonstrated, that control of inflammation by inhibition of 
(immune) cell activation and leukocyte influx resulted in improved disease outcome. 
Different therapies have been proposed that interfere with leukocyte recruitment at 
different levels. These include antibodies or small antibody fragments to neutralize 
proinflammatory cytokines, or functionally inhibit adhesion molecules on leukocytes 
and endothelial cells (1). Therapies that entered the market are among others directed 
to neutralize tumor necrosis factor (TNF)α activity in rheumatoid arthritis and Crohn’s 
disease (Infliximab, Remicade ®) and α4-integrin binding to very late antigen (VLA)-
4 (Natalizumab, Tysabri ®). Other “magic bullet” therapies, although successful in 
preclinical studies, showed limited outcome in clinical trials. A likely explanation 
for the observed lack of effects is that blocking one specific molecule involved in 
leukocyte recruitment can lead to functional replacement by alternative molecules. 
Moreover, since different leukocyte subsets employ different combinations of adhesion 
molecules, cytokines and chemokines for their extravasation and activation, inhibition 
of expression of only one of these molecules may not significantly alter the extent of 
leukocyte recruitment (for a review, see (2)).
A growth in understanding of the functional and molecular control of intracellular 
signal transduction during cell activation has led to a shift in drug development from 
antibodies and peptides that block specific molecules that control leukocyte – endothelial 
cell interaction to small chemical entities that affect inflammatory cell activation. In this 
thesis we studied the effects of selective interference with two prime proinflammatory 
intracellular signaling pathways nuclear factor κB (NF-κB) and p38 mitogen-activated 
protein kinase (MAPK) in endothelial cells employing low molecular weight chemical 
inhibitors and a gene therapy vector. NF-κB signal transduction blockade resulted in 
strong inhibition of adhesion molecule gene expression and only limited inhibition of 
cytokines and chemokines, while blockade of p38 MAPK signaling resulted in moderate 
(E-selectin) or no (vascular cell adhesion molecule-1 (VCAM-1), intracellular adhesion 
molecule-1 (ICAM-1)) effect on adhesion molecules while significant inhibition of 
cytokine and chemokine expression was observed. These experiments confirmed a 
major role for both NF-κB and p38 MAPK pathways in regulation of gene expression in 
endothelial cells as part of the inflammatory response induced by cytokines.
We hypothesized that blocking both pathways simultaneously would significantly 
enhance the pharmacological effect, and experimentally supported this hypothesis in 
our in vitro model system employing chemical inhibitors. Combining multiple drugs in 
a therapeutic regimen is a feasible approach which is at present under investigation in 
our laboratory. One potential drawback of freely administered (combinations of these) 
drugs may be the induction of toxicity in normal tissues, as both NF-κB and p38 MAPK are 
considered also of importance for normal cell homeostasis (3;4). To specifically direct 
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such a combination therapy to the endothelium in inflammatory sites, the drugs could 
be included in immunoliposomes harnessed with antibodies specifically recognizing the 
diseased endothelial cells. These targeted drug delivery systems require the candidate 
drugs to have a hydrophilic character, to prevent the drugs from redistribution prior 
to reaching the target upon systemic administration. Additionally, the candidate drugs 
should exert a proper pharmacological effect at concentrations that can be achieved 
by targeted drug delivery. A number of drugs used in our studies were effective at low 
micromolar concentrations. However, all compounds employed were hydrophobic by 
nature, which appeared to be the major limiting factor for application in a liposome-based 
drug delivery formulation. In general, new chemical entities in the drug development 
pipeline are selected for further study based on their pharmacological effects in cell 
systems. Since this quality is intricately associated with the ability to cross biological 
membranes (i.e., with a hydrophobic nature), many of the new kinase inhibitors that 
were excluded from further clinical testing due to unacceptable toxicity and as such 
are interesting candidates for targeted delivery, are not qualified for immunoliposomal 
delivery unless chemically modified.
Instead of an immunoliposome-based approach, we investigated in Chapters 5 
and 6 whether adenoviral gene therapy vectors could be considered for selective delivery 
of a therapeutic transgene that interferes with intracellular signaling. Recombinant 
adenoviruses have a number of important characteristics that make them useful as 
gene transfer tools for application in gene therapy (5). They are easy to propagate 
and can transduce a wide range of cells with high efficiency. Moreover, their genomes 
can accommodate relatively large fragments of DNA. The viral genome is maintained 
epichromosomally through numerous replication cycles and it is believed to not to affect 
host genes (6). These advantageous features have led to a rapid development of the 
field of recombinant adenoviruses for therapeutic application. Yet, despite promising 
results in the laboratory, these adenoviruses have not been extremely successful in 
clinical settings. One of the major reasons is the unrestricted distribution of adenoviral 
gene transfer to nontarget tissues, with markedly reduced therapeutic effects and 
vector-induced immunogenic toxicities. In our research we aimed to circumvent 
these problems by introducing activated endothelial cell-specific antibodies combined 
with polyethylene glycol (PEG) modification of the adenovirus capsid. This resulted 
in alteration of the natural viral tropism and selective transfer of the transgene into 
activated endothelial cells expressing E-selectin or VCAM-1. In nature, adenovirus 
infection occurs through the interaction of the viral fiber protein and its primary cell 
surface receptor, Coxsackie and adenovirus receptor (CAR) (7). We redirected this 
adenovirus interaction to alternative cell surface receptors which are inflammation 
induced. E-selectin is especially attractive due to its high and transient expression 
restricted to activated endothelial cells in microvasculature engaged in inflammatory 
processes. Another inflammation associated epitope, VCAM-1, was recently described 
as a potential target for specific drug delivery to activated endothelial cells (8). One of 
the drawbacks of E-selectin as a target epitope when considering clinical application 
may be its transient expression – when the patient presents in the clinic with (recurrent) 
disease, this adhesion molecule may already have been downregulated. In contrast, 
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VCAM-1 is often expressed at a later moment in the inflammatory process, and its 
expression is generally believed to be more prolonged. Yet, employing VCAM-1 as a 
target may have the intrinsic weakness that it is constitutively expressed e.g., in the 
kidney peritubular endothelium (Chapter 4), which may presents as a potential site for 
unwanted side effects of the targeted therapeutic. 
In our endothelium-directed gene therapy strategy we employed dominant-
negative inhibitor κB (dnIκB) as a transgene, which selectively blocked NF-κB signaling 
in activated endothelial cells. NF-κB signal transduction induces the expression of 
multiple downstream effector molecules including cell adhesion molecules (P- and E-
selectin, VCAM-1, ICAM-1), cytokines, and chemokines. These molecules serve as 
guidance for recruitment of different subsets of immune cells during inflammation. A 
dose of 104 viral particles per cell nearly abolished NF-κB signaling and consequently 
the expression of the inflammatory molecules, thereby confirming the potential of 
dnIκB inhibitory protein as an anti-inflammatory therapeutic protein with broad 
effector profile. We did observe anti-inflammatory effects of the retargeted dnIκB 
adenovirus in a mouse model of glomerulonephritis (Chapter 6), yet some issues 
remain unsolved. For example, the number of viral particles delivered per cell in vivo 
is unknown. Moreover, we do not know whether a dose of viral particle per cell needed 
in glomerular endothelium to silence the NF-κB pathway is similar to the dose needed 
in human umbilical vein endothelial cells (HUVEC). 
Of interest is the observation that, when combining virus targeted NF-
κB inhibition with chemical drug based inhibition of p38 MAPK (Fig. 1), a complete 
blockade of gene expression could not be achieved, similar to the observations 
reported in Chapter 3. In addition, in Chapter 4, we observed that blockade of NF-
κB in TNFα activated HUVEC resulted in an increase in p38 MAPK activity (Chapter 
4, Fig. 4). This data imply that in endothelial cells signaling pathways additional to 
NF-κB and p38 MAPK prevail when others are inhibited. To elucidate the intracellular 
downstream events responsible for these observations, more detailed investigations 
on kinase activation profiles during cell activation and drug treatment are necessary. 
Novel approaches including kinase array assays and progress in proteomics and 
computer technology need to be employed to learn to understand complexity and 
kinetics of kinase activities in a cell under normal conditions, and in response to stress 
and therapeutic intervention.
The endothelium on one hand is considered as an integrated system covering 
all blood vessels that traverse the body, while on the other hand, each vascular bed has 
unique structural and functional properties with consequences for endothelial behavior 
(Fig. 2). Each tissue contains its own highly specialized microvascular endothelium, which 
displays organ-specific characteristics. For example, in the brain the tightly connected 
nonfenestrated continuous endothelium from the blood brain barrier is highly specialized 
to protect the neural tissue from fluctuations in blood composition. In contrast, the 
fenestrated endothelium in the glomeruli in the kidney is highly specialized to facilitate 
the blood filtration process. While knowledge regarding macrovascular endothelial 
physiology and dysfunction in cardiovascular diseases has increased considerably in 
the last decades, the molecular complexity of the microvascular endothelium has not 
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been extensively studied. Since inflammatory processes and angiogenic remodeling 
mainly take place in the microvasculature, a detailed understanding of the behavior of 
these cells in health and disease, and in response to drug treatment will be essential 
for the development of clinically effective therapeutic regimens. Therefore we set out 
to investigate the molecular make-up of microvascular endothelial cell subsets within 
one particular organ. We were able to study endothelium in its in vivo context using 
a new approach in which we combined endothelial cell laser microdissection with 
quantitative RT-PCR gene expression profiling. This experimental approach is of interest 
for scientists working in basic (endothelial) biomedicine research, to unravel the in vivo 
mechanisms underlying (vascular) diseases, and in the different expertise fields of drug 
development. In this thesis research, we applied the microdissection strategy combined 
with quantitative gene expression analysis to approach different subsets of endothelial 
cells in the kidney in different (patho)physiological and pharmacological conditions. 
We showed that in basal conditions subsets of endothelial cells exerted differential 
patterns of endothelial marker gene expression. For example, the ratio of CD31 : 
Figure 1. Effect of simultaneous inhibition of NF-κB and p38 MAPK signaling on 
inflammatory gene expression in HUVEC. TNFα-activated HUVEC were transfected with AbEsel-
PEG-AddnIκB and treated with 1 µM RWJ67657 before activation with interleukin (IL)-1β (scheme 
represents the experimental protocol). Gene expression was analyzed using quantitative RT-PCR 
and data were adjusted to the expression of GAPDH.
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VE-cadherin was approximately 2, 0.7, and 1 in arterioles, respectively glomerular 
and venular endothelium. Both genes are involved in maintaining endothelial integrity 
and in signaling events during inflammatory and angiogenic episodes. Possibly, these 
differences in gene expression levels, which were substantiated by protein expression 
using immunohistochemistry, have a functional meaning which is unknown at present. 
The observation that endothelial marker genes are differentially expressed furthermore 
has implications for their use as endothelial housekeeping gene/RNA reference in 
laser microdissection microscopy/quantitative RT-PCR protocols as well as for use in 
immunohistochemical identification of endothelial subsets prior to dissection.
The biology of different endothelial cell types has been extensively studied 
in cell culture systems. Although these studies added to our understanding of basic 
endothelial cell behavior, they miss the actual context of the environment. The 
endothelial surroundings are essential in maintenance of function in the particular 
tissues. For example, in glomeruli, podocytes and mesangial cells were both shown to 
communicate with glomerular endothelium to support the physiological filtration function 
of the capillaries (9). In inflammation, microvascular endothelial cells become activated 
by proinflammatory cytokines, of which the local concentrations are determined by the 
pathophysiological environment. Endothelial cells respond to this activation by quick 
and well-organized changes in gene expression, with their protein products serving 
to recruit different subsets of immune cells. We shed some light on the complexity of 
this system when studying the in vivo microvascular reaction to TNFα. Not all vascular 
beds in the organs expressed the expected combination of selectins and integrin- and 
immunoglobulin super family adhesion molecules. Possibly, the 2h time frame was too 
short to mount a complete microvascular reaction, although all inflammatory genes 
Figure 2. Organization of the vascular tree. Circulating blood travels from arteries through 
arterioles and capillaries to (post-capillary) venules, from where it enters the veins. All vascular 
beds are lined by endothelial cells that exert characteristic functions depending on their location 
in the body.
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studied were upregulated at the mRNA level at this time point. It is therefore likely, that 
immune cell subset recruitment is endorsed by a site restricted control of endothelial 
gene expression. Moreover, during the inflammatory event, the recruitment of the 
leukocytes by cell-cell contact with the endothelium can also influence endothelial cell 
behavior. For example during inflammation in the central nervous system, ICAM-1-
mediated signaling in brain endothelial cells is a crucial regulatory step in the process 
of lymphocyte migration through the blood brain barrier (10). As such, this represents 
an additional complexity in in vivo microvascular behavior which cannot be easily 
mimicked in in vitro culture systems. 
In our in vivo studies on endothelial cell responses to drug treatment during 
acute inflammatory activation we observed that the inflammatory genes affected by 
the treatment did not represent the ones that responded in the isolated endothelial 
cell system in vitro. Among the striking differences was the absence of effects of 
dexamethasone (DEX) on cytokine-induced adhesion molecule expression in HUVEC, 
while in vivo the drug significantly inhibited the expression of a number of these 
genes. In contrast, the activator protein (AP)-1/NF-κB inhibitor MOL-294 exhibited 
tremendous effects on adhesion molecules in vitro, while it was devoid of effects in 
vivo. These data demonstrated that the in vitro pharmacological activity of the anti-
inflammatory drugs were not representative of the effects in vivo, where endothelial 
cells are present in their natural context and experience direct interaction with blood 
and blood borne entities. Although we studied the effects of drug pretreatment on acute 
proinflammatory endothelial activation in a relatively short (2h) time frame, it cannot 
be excluded that the responses in vivo have been influenced by effects of the drugs on 
e.g., leukocytes. Their intricate interaction with the microvascular endothelium during 
each circulation event may (indirectly) affect endothelial behavior. Irrespective of the 
reason for the discrepancy observed, the conclusion remains justified that in vitro 
endothelial responses to drugs are not per se indicative of their responses in vivo. 
Careful in vivo evaluation of the pharmacological effects in diseased cells within an 
organ is warranted to prevent misinterpretation of data. 
It is important to realize that the added therapeutic value of pharmacological 
interference with activated endothelial cells still needs to be determined. It has not 
been clearly established yet, whether chronic inflammation will resolve by inhibiting 
endothelial cell activation only. Research in our laboratory showed that treatment with 
E-selectin directed immunoliposomes containing DEX strongly reduced glomerular 
proinflammatory gene expression in mice suffering from glomerulonephritis (11). 
Moreover, the delivered DEX reduced renal injury as evidenced by a reduction in blood 
ureum nitrogen levels and decreased glomerular crescent formation. This study not 
only exemplified the use of innovative techniques to study endothelial vascular bed 
specific responses to targeted therapy, it also demonstrated one of the first attempts 
to bridge microvascular gene expression profiles with actual disease outcome. 
 In summary, one can conclude that pharmacological intervention with 
microvascular endothelial cell activation has therapeutic potential. However, several 
issues need further attention, including drug choice in relation to the vascular bed 
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aimed at, formulation of the drugs, the timing of administration and optimal dose, as 
well as the choice of (surrogate) biomarker for measuring effects. Knowledge about this 
will contribute to the development of improved therapies for inflammatory diseases.
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